Mesoblast (MESO) Income from Continuing Operations (2014 - 2023)
Mesoblast (MESO) posted quarterly Income from Continuing Operations of 21575000.0 for Q2 2023, down 2.34% year-on-year from 22092707.78 in Q2 2022, and down 15.42% on a QoQ basis from 18692000.0 in Q1 2023.
Mesoblast (MESO) Income from Continuing Operations (2014 - 2023) Analysis & Trends
Mesoblast (MESO) has reported Income from Continuing Operations for 10 consecutive years, with 21575000.0 the latest figure, recorded in Q2 2023.
- Quarterly Income from Continuing Operations fell 2.34% year-over-year to 21575000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 81889000.0 (up 10.35% YoY) and the FY2025 annual result came in at 102142000.0, down 16.13% from the prior year.
- Income from Continuing Operations eased to 21575000.0 in Q2 2023 per MESO's latest filing, from 18692000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for MESO reached as high as 5484000.0 in Q3 2019 and fell as low as 32610000.0 in Q2 2020.
- A 5-year average of 21901333.33 and a median of 22172000.0 in 2021 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2019 — Income from Continuing Operations soared 71.87% — and 2020, when it tumbled 347.56%.
- Year by year, Income from Continuing Operations stood at 24584000.0 in 2019, then decreased by 3.9% to 25544000.0 in 2020, then dropped by 2.2% to 26105000.0 in 2021, then gained by 5.66% to 24628000.0 in 2022, then grew by 12.4% to 21575000.0 in 2023.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 21575000.0, 18692000.0, and 24628000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -21.58 Mn |
| Mar 31, 2023 | -18.69 Mn |
| Dec 31, 2022 | -24.63 Mn |
| Sep 30, 2022 | -16.99 Mn |
| Jun 30, 2022 | -21.08 Mn |
| Mar 31, 2022 | -21.39 Mn |
| Dec 31, 2021 | -26.11 Mn |
| Sep 30, 2021 | -22.77 Mn |
| Jun 30, 2021 | -20.55 Mn |
| Mar 31, 2021 | -26.71 Mn |
| Dec 31, 2020 | -25.54 Mn |
| Sep 30, 2020 | -24.54 Mn |
| Jun 30, 2020 | -32.61 Mn |
| Mar 31, 2020 | -15.26 Mn |
| Dec 31, 2019 | -24.58 Mn |
| Sep 30, 2019 | -5.48 Mn |
| Jun 30, 2019 | -20.73 Mn |
| Mar 31, 2019 | -24.97 Mn |
| Dec 31, 2018 | -24.60 Mn |
| Sep 30, 2018 | -19.50 Mn |